论文部分内容阅读
目的:探讨血必净注射液联合酚妥拉明、多巴酚丁胺治疗重症肺炎合并心力衰竭的疗效及安全性。方法:选取杭州市第九人民医院2017年1月至2019年12月收治的重症肺炎合并心力衰竭患者200例为研究对象，采用随机数字表法分为对照组、观察组各100例。对照组采用酚妥拉明联合多巴酚丁胺治疗，观察组在对照组的基础上联合血必净注射液治疗。比较两组临床疗效，治疗前后C反应蛋白（CRP）、白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）水平变化，左心室射血分数（LVEF）、心肌肌钙蛋白（cTnI）、B型脑钠肽（BNP）水平变化以及不良反应发生率。结果:观察组总有效率为94.0%（94/100），高于对照组的85.0%（85/100）（χn 2=4.31，n P 0.05）；治疗后，观察组CRP、IL-6、TNF-α分别为（56.29±10.78）ng/L、（75.60±13.24）ng/L、（130.42±24.79）ng/L，均低于对照组的（70.52±13.10）ng/L、（87.46±15.68）ng/L、（164.51±28.47）ng/L，差异均有统计学意义（ n t=8.38、5.77、9.03，均n P < 0.001）；观察组LVEF［（58.30±8.65）%］高于对照组［（54.29±7.9）%］，cTnI［（1.87±0.52）μg/L］、BNP［（218.42±24.23）ng/L］均低于对照组［（2.40±0.65）μg/L、（325.61±36.97）ng/L］，差异均有统计学意义（ n t=-3.42、6.36、24.25，均n P 0.05）。n 结论:血必净注射液联合酚妥拉明、多巴酚丁胺治疗重症肺炎合并心力衰竭的临床疗效确切，可抑制炎性因子的表达，改善心功能，不良反应发生率低，安全性高。“,”Objective:To investigate the efficacy and safety of n Xuebijing injection combined with phentolamine and dobutamine for the treatment of severe pneumonia complicated by heart failure.n Methods:A total of 200 patients with severe pneumonia complicated by heart failure treated in Hangzhou Ninth People\'s Hospital from January 2017 to December 2019 were included in this study. They were randomly allocated into the control and observation groups (n n = 100/group). The control group was treated with phentolamine and dobutamine. The observation group was treated with n Xuebijing injection combined with phenolamine and dobutamine. Clinical efficacy, changes in C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), left ventricular ejection fraction (LVEF), cardiac troponin I (cTnI), and B-type natriuretic peptide (BNP) post-treatment relative to pre-treatment, and the incidence of adverse reactions were compared.n Results:Total response rate was significantly higher in the observation group than in the control group [94.0% (94/100) n vs. 85.0% (85/100), n χ2 = 4.31, n P 0.05). CRP, IL-6, TNF-α post-treatment in the observation group were (56.29 ± 10.78) ng/L, (75.60 ± 13.24) ng/L, (130.42 ± 24.79) ng/L respectively, which were significantly lower than those in the control group [(70.52 ± 13.10) ng/L, (87.46 ± 15.68) ng/L, (164.51 ± 28.47) ng/L, n t = 8.38, 5.77, 9.03, all n P < 0.001]. LVEF post-treatment was significantly higher in the observation group than in the control group [(58.30 ± 8.65)% n vs. (54.29 ± 7.9)%, n t = -3.42, n P < 0.05]. cTnI and BNP post-treatment in the observation group were (1.87 ± 0.52) μg/L and (218.42 ± 24.23) ng/L, respectively, which were significantly lower than those in the control group [(2.40 ± 0.65) μg/L, (325.61 ± 36.97) ng/L, n t = 6.36, 24.25, both n P 0.05].n Conclusion:Xuebijing injection combined with phentolamine and dobutamine is effective in the treatment of severe pneumonia complicated by heart failure. The combined therapy inhibits the expression of inflammatory factors, improves cardiac function, has a low incidence of adverse reactions, and is highly safe.n